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Monthly Extended-Release Risperidone (RBP-7000) in the
Treatment of Schizophrenia
Results From the Phase 3 Program
Anne Andorn, MD,* Jay Graham, PharmD,* John Csernansky, MD,† John W. Newcomer, MD,‡
Sunita Shinde, MD,* Gilbert Muma, PhD,* Christian Heidbreder, PhD,* and Maurizio Fava, MD§
Abstract:
Purpose/Background: The Phase 3 program for RBP-7000, a once-
monthly subcutaneous (SC) extended-release risperidone formulation
approved for treatment of schizophrenia, consisted of a double-blind
placebo-controlled trial (previously reported) and a 52-week open-label
study of monthly RBP-7000 120 mg. The primary objective of the
open-label study was to evaluate the long-term safety and tolerability
of RBP-7000 in adults with schizophrenia. A secondary objective was
to assess long-term maintenance of effectiveness.
Methods/Procedures: The 52-week Phase 3 open-label study
(NCT02203838) enrolled 92 rollover participants from the double-blind
trial (NCT02109562) and 408 stable (Positive and Negative Syndrome
Scale [PANSS] total score,≤70) de novo participants. Participants received
up to 13 monthly SC injections of RBP-7000 120 mg. Safety assessments
included treatment-emergent adverse events, injection-site assessments,
vital signs, laboratory and ECG parameters, extrapyramidal symptoms,
and suicidality. Clinical outcomes included the PANSS and Clinical
Global Impression—Severity.
Findings/Results: Overall, 367 participants (73.4%) reported 1 or more
treatment-emergent adverse event; the most common were injection-site
pain (13.0%) andweight increase (12.8%).Most participants (>80%) expe-
rienced no injection-site reactions. No clinically meaningful changes were
observed in laboratory or electrocardiogram values, vital signs, extrapyra-
midal symptoms, or suicidality. Over 12months of exposure, mean PANSS
scores continued to improve in rollover participants and remained stable
among de novo participants. Mean Clinical Global Impression—Severity
scores remained stable among all participants.
Implications/Conclusions: Except for anticipated injection-site re-
actions, RBP-7000 demonstrated a favorable safety and tolerability
profile similar to oral risperidone. Notably, PANSS scores continued
to improve for participants from the pivotal study and remained stable
for de novo participants.
Key Words: antipsychotic, schizophrenia, extended-release depot,
long-term safety
(J Clin Psychopharmacol 2019;39: 428–433)
S chizophrenia remains a leading cause of disabilityworldwide.
1,2
Current first-line treatment involves the use of oral second-
generation antipsychotics, including risperidone,3 yet nonadherence
with daily oral medication is common and is associated with in-
creased risk of relapse.4,5 Depot medications, such as long-acting
injectable antipsychotics, have been developed as alternatives to
oral antipsychotics and have been shown to facilitate adherence,6,7
increase quality of life,8,9 and decrease rehospitalizations.10,11
RBP-7000, a once-monthly subcutaneous (SC) extended-release
injectable suspension, is a newly Food and Drug Administration–
approved risperidone formulation designed to achieve clinically
relevant therapeutic plasma concentrations on the first day of dos-
ing, with no need for a loading dose or supplemental oral dosing.
The efficacy and safety of RBP-7000 were previously established
in an 8-week, double-blind, placebo-controlled trial conducted in
adults with acute exacerbation of schizophrenia.12 Compared with
placebo, monthly SC RBP-7000 (90 and 120 mg) significantly im-
proved Positive and Negative Syndrome Scale (PANSS)13 total
score and the Clinical Global Impression—Severity (CGI-S)14
score. Participants treated with RBP-7000 also showed significant
improvements in health-related quality of life, physical functioning,
and social integration scores.15 Treatment was generally well tol-
erated, with a safety profile consistent with previous reports of
oral or injectable risperidone,16,17 with the exception of expected
injection-site reactions.
The primary objective of the current study was to assess the
long-term safety and tolerability of SC injections of RBP-7000 in
patients with schizophrenia; however, a secondary objective was
to assess long-term maintenance of effectiveness.
MATERIALS AND METHODS
Study Conduct and Design
This 52-week, multicenter, Phase 3, open-label, outpatient
study (NCT02203838) was conducted at 50 sites in the United
States between June 2014 and September 2016 in accordancewith
the International Conference on Harmonisation Good Clinical
Practice guidelines, Food and Drug Administration regulations
governing clinical study conduct, and the Declaration of Helsinki
(2013). The study protocol, all protocol amendments, written
study patient information, informed consent form, and all other
appropriate study-related information were reviewed and approved
by an institutional review board.
The study enrolled patientswith acute exacerbations of schizo-
phrenia who had completed a double-blind trial (“rollover” partici-
pants from study NCT02109562)12 in which they had received
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2 monthly SC injections of either placebo, RBP-7000 90 mg, or
RBP-7000 120 mg. The present study also included newly enrolled
(de novo) participants with stable schizophrenia (Supplemental
Fig. 1, Supplemental Digital Content 1, http://links.lww.com/JCP/
A583). De novo participants already receiving 3 or 4 mg/d oral ris-
peridone began the study at day 1; those receiving oral risperidone
at a dosage other than 3 or 4mg/d entered a 7-day conversion period
in which they were titrated to an oral risperidone dosage of 3 or
4 mg/d. De novo participants receiving antipsychotic medication
other than oral risperidone entered a 14-day run-in period during
which their current antipsychotic therapy was down-titrated and
oral risperidone was up-titrated to a dosage of either 3 or 4 mg/d
at the investigator's discretion.
During the open-label treatment phase, rollover participants
received up to 11 monthly SC injections of RBP-7000 120 mg
and de novo participants received up to 13 injections. At the
investigator's discretion, participants were allowed a single dose
modification to 90 mg for tolerability and a subsequent single
dose modification to 120 mg if psychiatric symptoms worsened
(PANSS total score >70 or a 20% increase in PANSS total score
from the last 120 mg dose assessment).
Participants
Adults 18 to 65 years (inclusive) who met Diagnostic and
StatisticalManual ofMental Disorders, Fourth Edition, Text Revi-
sion criteria for schizophrenia were eligible. Rollover participants
from the double-blind study had been treated for 8 weeks with 2
injections of RBP-7000 or placebo in an inpatient setting after
an acute exacerbation of schizophrenia as described previously.12
Completers from that study were allowed to enroll in the present
study. De novo participants were required to have a diagnosis of
schizophrenia, considered stable with a PANSS total score of less
than or equal to 70 at screening and were otherwise healthy based
on physical examination. De novo participants with suicidal
ideation (within 6 months) or behavior (within 1 year) based
on Columbia Suicide Severity Rating Scale18 assessment, or
with a significant risk of suicide in the opinion of the investigator,
were excluded.
Exclusion criteria for both the double-blind and open-label
studies included previous treatment with clozapine, current use
of oral risperidone (≥6 mg/d), Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, Text Revision criteria for al-
cohol or substance abuse, and clinically relevant abnormalities of
liver function or QTc interval. Concomitant use of CYP2D6 in-
hibitors or inducers or any long-acting injectable antipsychotic
medication (other than the study drug) was prohibited during the
treatment period; participants were discontinued if antipsychotic
rescue treatment became necessary. With these exceptions, partic-
ipants could continue any previously prescribedmedications other
than antipsychotics. The use of benzodiazepines, propranolol, and
anti-parkinsonian medication was allowed during treatment ex-
cept within 12 hours before PANSS, CGI-S, or extrapyramidal
symptom (EPS) scale assessments.
Safety Assessments
Safety assessments included treatment-emergent adverse events
(TEAEs), local injection-site tolerability, clinical laboratory values,
vital signs, and electrocardiograms (ECGs), as well as measurements
of body weight, height, body mass index (BMI), and abdominal
fat, measured by waist-hip ratio. Extrapyramidal symptoms were
assessed using Abnormal Involuntary Movement Scale,19 Simpson-
Angus Scale,20 and Barnes Akathisia Rating Scale.21 Suicidal idea-
tion and behavior were monitored using Columbia Suicide Severity
Rating Scale.
Local injection-site grading was performed within 10 minutes
of each injection and at 3 hours (±10 minutes) postinjection for
pain, tenderness, erythema/redness, and induration/swelling; each
symptom was assigned a severity grade of none (grade 0) to poten-
tially life-threatening (grade 4). Injection-site painwas alsomeasured
using the Injection-site Pain Visual Analog Scale (VAS), a 2-item,
participant-reported questionnaire with responses (0–100 mm) rang-
ing from “no injection-site pain” to “worst imaginable injection-site
pain.”22 Visual Analog Scale assessments were completed by the
participant after each RBP-7000 injection at 1 (±15 seconds), 5
(±2), 30 (±2), and 60 (±2) minutes postinjection.
Effectiveness Assessments
The long-term effects of RBP-7000 on schizophrenia symp-
toms (secondary outcomes) were evaluated in this long-term study
using PANSS total score, PANSS Positive Scale, Negative Scale
and General Psychopathology Scale scores, and CGI-S score col-
lected at baseline, day 29, day 169, and at the end of study (EOS).
Statistical Analyses
A descriptive analysis of the long-term effects of RBP-7000
on safety, tolerability, and efficacy was performed on the safety
population, which comprised all participants who received 1 or
more open-label RBP-7000 injections. The results are presented
for all participants and also by the following study groups: rollover
(by double-blind treatment group) and de novo participants. Base-
line was defined as the last nonmissing measurement taken before
the first injection (including unscheduled assessments). Data are as
observed with no imputation of missing data and are presented as
change from baseline to EOS (defined as the last visit) or to the
end of treatment (EOT, defined as EOS for completers and early
termination visit for participants who discontinued). For rollover
participants, safety assessments performed at the EOS visit of the
previous double-blind study (screening visit for open-label study)
served as the preinjection assessments for the open-label study.
RESULTS
Disposition and Demographics
A total of 500 participants were eligible for study participation
(Supplemental Fig. 2, Supplemental Digital Content 2, http://links.
lww.com/JCP/A584); 92 had completed the previous double-blind
study, placebo (30.4%, n = 28), RBP-7000 90 mg (33.7%,
n = 31), or RBP-7000 120 mg (35.9%, n = 33), and 408 were
de novo participants with stable schizophrenia. In this study,
rollover participants received up to 11 injections of RBP-7000
120 mg, and de novo participants received up to 13 injections
of RBP-7000 120 mg. Overall, 234 participants (46.8%) completed
this study, with the proportion of rollover placebo participants com-
pleting being approximately half that of the other groups. The most
common reasons for discontinuation were withdrawal of consent
(22.4%), adverse events (11.4%), and lost to follow-up (9.0%).
Demographic and baseline clinical characteristics were comparable
across study groups (Supplemental Table 1, Supplemental Digital
Content 3, http://links.lww.com/JCP/A585). The overall dropout
rate observed in this study was 53.2%, which was consistent




Overall, 326 participants (65.2%) were exposed to RBP-7000
for 6 months or longer including 48.0% of de novo participants
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exposed for 1 year or longer. Themean duration of treatment among
rollover participants (11 injections) was as follows: 161.9 days for
rollover placebo, 196.6 days for rollover RBP-7000 90 mg, and
196.6 days for rollover RBP-7000 120mg (including 58 days of ac-
tive treatment during the double-blind study). For de novo partici-
pants (13 injections), mean exposure was 259.3 days.
Adverse Events
The majority of participants (367; 73.4%) reported 1 or more
TEAEs (Supplemental Table 2, Supplemental Digital Content 4,
http://links.lww.com/JCP/A586), most of which were mild (29.6%)
to moderate (39%) with only 4.8% reporting 1 or more severe
TEAEs. The most common TEAEs (≥5%) were injection-site pain
(13.0%) and weight increase (12.8%), schizophrenia (7.8%), in-
somnia (7.0%), injection-site nodule (6.8%), akathisia (6.0%),
injection-site induration (5.8%), upper respiratory tract infection
(5.2%), and headache (5.0%). Fifty-eight participants (11.6%)
discontinued the study owing to TEAEs, most commonly owing
to schizophrenia (2.0%), akathisia (0.8%), weight increase (0.8%),
tremor (0.6%), and galactorrhea (0.6%). Only 2 participants
discontinued owing to injection-site reactions (tenderness and
nodule). Treatment-emergent adverse events attributed to
RBP-7000 were injection-site pain (12.8%), weight increase
(11.4%), injection-site nodule (6.8%), injection-site induration
(5.8%), and akathisia (5.8%).
Thirty-four participants (6.8%) experienced a serious ad-
verse event (SAE), none of which was considered related to study
drug. Four deaths were reported (pulmonary embolism, cardiac
arrest, head trauma, and increased psychosis), none of which
were considered related to study drug by either the investigator
or by adjudication.
TEAEs Among Participants With a Dose Modification
Of 86 participants who had a dose modification to 90 mg
(77 de novo participants [18.9%], 3 rollover placebo [10.7%],
3 rollover RBP-7000 90 mg [9.7%], and 3 rollover RBP-7000
120 mg [9.1%]), 42 (48.8%) did so owing to a TEAE. The most
commonly reported TEAEs included injection-site pain (14.0%),
insomnia (11.6%), schizophrenia (10.5%), akathisia (10.5%), and
blood prolactin increased (10.5%). The severity was mostly mild
(27.9%) or moderate (57.0%), with 5 participants (5.8%) reporting
a severe TEAE (weight increase, n = 2; dry mouth, sedation, and
deep vein thrombosis, n = 1 each).
Injection-Site Tolerability
The maximum reported intensity for injection-site assess-
ments made by site staff for pain, tenderness, erythema/redness,
and induration/swelling, was none (grade 0) for 81.8% and
97.4% of participants immediately and at 3 hours postdose, re-
spectively. A total of 18.0% of participants reported a mild (grade
1) injection-site reaction immediately after injection. One roll-
over RBP-7000 120 mg participant and 1 de novo participant
each reported a single instance of severe injection-site tenderness
immediately after injection. Injection-site tolerability symptoms
were mostly resolved within 3 hours postinjection, with only
2.5% of participants experiencing mild pain, 4.3% tenderness,
3.9% induration/swelling, and 0.8% erythema/redness at 3 hours.
Fewer participants reported burning/stinging at 1 minute af-
ter injection on day 337 as compared with day 1, decreasing from
43.4% on day 1 to 35.7% on day 337. Supplemental Figure 3
(Supplemental Digital Content 5, http://links.lww.com/JCP/
A587) displays the participant-reported injection-site pain VAS
scores at 1, 5, 30, and 60 minutes after the first injection for
the de novo and rollover subgroups. For all subgroups, there
was a notable decrease in pain between 1 and 5 minutes postin-
jection, with median pain intensity VAS scores ranging from
3.5 to 14 at 1 minute postinjection, dropping to between 1
and 3 at the 5 minutes postinjection time point.
The median/mean injection-site pain VAS score for the total
population decreased from 13.0/24.9 one minute after the first in-
jection to 2.5/15.8 one minute after the 11th injection (day 281),
suggesting pain intensity decreased with subsequent injections.
Body Weight, BMI, and Abdominal Fat
During the initial 3 months of treatment, mean body weight
increased modestly in treatment-naive participants (de novo
[1.9 kg], rollover placebo [1.6 kg]) and then stabilized for the re-
mainder of the study. Mean body weight remained stable for par-
ticipants in the rollover RBP-7000 120 mg group and decreased
modestly for those in the rollover RBP-7000 90 mg group, with
mean (SD) changes from baseline in body weight of 0.7 (5.0)
kg and −1.5 (5.8) kg, respectively, by EOT. Box plots of the mean
and median change from baseline for weight, although showing
wide variability, show a normal distribution, which should be gen-
eralizable (Supplemental Fig. 4, Supplemental Digital Content
6, http://links.lww.com/JCP/A588).
At EOT, 22.1% (94/426) of all participants had a ≥7% in-
crease in body weight from baseline, with a higher incidence in
de novo participants (24.6%) than rollover placebo (9.5%), rollover
RBP-7000 90 mg (13.8%) or rollover RBP-7000 120 mg (10.0%).
Treatment-emergent adverse events of weight increase were re-
ported for 12.8% of participants; however, only 4 participants
(0.8%) withdrew because of this adverse event. Mean differences
from baseline to EOT in BMI and abdominal fat were small and
similar across study groups (Supplemental Table 3, Supplemental
Digital Content 7, http://links.lww.com/JCP/A589).
Metabolic Parameters and Prolactin Levels
Small mean changes from baseline to EOTof unknown clini-
cal significance were observed in glucose, HbA1c, and cholesterol
levels (Supplemental Table 3, Supplemental Digital Content 7,
http://links.lww.com/JCP/A589). A post hoc shift analysis of serum
glucose showed a total of 20 de novo participants (9.2%) and 4 roll-
over participants (4.3%) had a shift in fasting glucose levels from
less than 100 mg/dL to greater than 126 mg/dL at any time during
the study. Treatment-emergent adverse events associated with met-
abolic changes occurring in more than 1% of all participants were
type 2 diabetes mellitus (2.0%) and diabetes mellitus (1.4%). Box
plots of mean andmedian change from baseline for total cholesterol
and glucose also show a normal distribution, confirming the previ-
ous data (data not shown).
The overall incidence of markedly abnormal postbaseline
prolactin values (≥3 times the upper limit of normal [ULN]) was
28.8% for females and 3.8% for males. Most females with prolac-
tin values less than or equal to 3 times the ULN at baseline re-
mained in that range throughout the study (62.1%) or shifted to
greater than 3 times the ULN to less than or equal to 6 times
the ULN (16.3%). The majority (94.9%) of males with prolactin
values less than or equal to 3 times the ULN at baseline remained
within that range. Few participants had TEAEs pertaining to ele-
vated prolactin, including blood prolactin increased (3.0%), galac-
torrhea (2.8%), hyperprolactinemia (1.4%), and blood prolactin
abnormal (0.2%).
Suicidality
Mean suicidal ideation scores and suicidal intensity ratings
through EOS were generally comparable with or lower than those
at baseline. No participant committed suicide during the study; 1
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de novo participant (0.2%) had an SAE of suicide attempt. There
were 6 participants (1.2%) with TEAEs of suicidal ideation, none
considered related to study drug: 2 participants with treatment-
emergent SAEs that led to study discontinuation, 2 with treatment-
emergent SAEs that did not lead to discontinuation, and 2 with
TEAEs not considered serious.
Additional Safety Measures and EPS
No clinically meaningful differences were noted in mean
changes from baseline to EOT for any laboratory test results,
blood pressure, heart rate, or ECG parameters (Supplemental
Table 3, Supplemental Digital Content 7, http://links.lww.
com/JCP/A589). The only ECG-associated TEAE occurring in
more than 1 participant was mild or moderate electrocardiogram
QT prolonged (n = 4); nonewere serious nor resulted in discontin-
uation. No clinically meaningful changes from baseline to EOT
were observed in Barnes Akathisia Rating Scale, Abnormal Invol-
untaryMovement Scale, or Simpson-Angus Scale scores (Supple-
mental Table 3, Supplemental Digital Content 7, http://links.lww.
com/JCP/A589). Treatment-emergent adverse events potentially
pertaining to EPS in more than 1% of participants were akathisia
(6.0%), tremor (2.0%), extrapyramidal disorder (1.8%), and mus-
cle spasms (1.2%); none were serious.
Effectiveness Assessments
Mean PANSS total scores at baseline were 58.0 for the de
novo group and ranged from 71.0 to 76.4 for the 3 rollover groups
(Supplemental Fig. 5A, Supplemental Digital Content 8, http://
links.lww.com/JCP/A590 [double-blind results also presented to
illustrate overall clinical course]). Notably, mean (SD) change from
baseline to EOS for rollover participants was −20.2 (15.6) for pla-
cebo, −12.5 (15.5) for RBP-7000 90 mg, and −10.9 (13.2) for
RBP-7000 120 mg; however, the number of evaluable participants
in the placebo group was small. Among de novo participants,
PANSS total scores remained stable throughout the study (mean
[SD] change from baseline to EOS −0.4 [8.7]).
Evaluating the rollover participants for each PANSS subscale,
a decrease from baseline to EOS was observed in each group, in-
cluding those who had received placebo in the double-blind study.
Mean (SD) changes from baseline to EOS on the PANSS Positive
Scale score were −7.8 (5.5), −3.7 (4.1), and −3.7 (3.5) among roll-
over participants previously treated with placebo, RBP-7000
90 mg, or RBP-7000 120 mg, respectively. For the PANSS Nega-
tive Scale score, mean (SD) changes from baseline to EOS
were −4.0 (5.9) for placebo, −4.1 (4.6) for RBP-7000 90 mg,
and −0.9 (3.8) for RBP-7000 120mg. For the PANSSGeneral Psy-
chopathology Scale score, mean (SD) changes from baseline to
EOS were −8.3 (7.0), −4.7 (9.0), and −6.4 (7.9) for placebo,
RBP-7000 90 mg, and RBP-7000 120 mg, respectively.
Among de novo participants, PANSS subscale scores re-
mained generally stable throughout the study, with mean (SD)
changes from baseline to EOS of −1.3 (3.3) for PANSS Positive
Scale, 1.3 (3.6) for PANSS Negative Scale, and −0.4 (5.0) for
PANSS General Psychopathology Scale. For all participants,
CGI-S scores also remained stable throughout the study (Supple-
mental Fig. 5B, Supplemental Digital Content 8, http://links.lww.
com/JCP/A590).
DISCUSSION
Depot medications have been useful in maximizing treat-
ment adherence and ameliorating the negative consequences of
nonadherence in the long-term treatment of schizophrenia. Partic-
ipants switching from shorter-acting oral medications to long-
acting injectable formulations have shown greater adherence,6,27
fewer hospitalizations,8,9 less inpatient health care resource utili-
zation, and decreased medical costs.7 RBP-7000 is the first once-
monthly SC risperidone injectable that demonstrated efficacy
without requiring loading doses or supplemental oral dosing. In this
52-week study of participants enrolled from a recent acute inpatient
study and from outpatient settings, treatment with RBP-7000 SC
injections administered monthly was well tolerated and resulted in
improved (rollover) or stable (de novo) clinical outcomes. No new
safety signals were reported, and the safety results were consistent
with the known safety profile of oral risperidone.16
The most commonly reported TEAEs were injection-site
pain and weight increase. Pain assessments were mild or moderate
in severity and expected for SC injections. For most participants
(>80%), the maximum reported intensity for injection-site assess-
ments (pain, tenderness, erythema/redness, induration/swelling)
immediately or 3 hours postdose was none (grade 0). Because
self-reported injection-site pain median VAS scores were low,
and pain typically resolved within minutes after the injection, re-
sults from this long-term study suggest that injection-site reactions
or discomfort are unlikely a major obstacle to long-term adherence
with RBP-7000.
Exposure to antipsychotics can be associated with a signifi-
cant increase in bodyweight,28,29 making risk of significant weight
gain a concern among patients with schizophrenia, caregivers, and
clinicians. During the previous double-blind study, participants in
all treatment groups experienced an increase in body weight,12
with mean gains of 2.8 kg in those receiving placebo and 5.1 kg
and 4.7 kg in participants receiving RBP-7000 90 mg and
RBP-7000 120 mg, respectively. In the current long-term open-
label trial, participants who had not received RBP-7000 previously
experienced a modest increase in mean weight (1.6–1.9 kg) during
the first 3 months of treatment, whereas body weight remained sta-
ble in rollover participants who had received RBP-7000 in the
double-blind study.Weight remained stable or declined to some de-
gree in all study groups during open-label months 3 to 12. There-
fore, prolonged exposure to RBP-7000 may not worsen the initial
weight gain that may be observed upon initiation of treatment.
Although hyperprolactinemia is commonly observed with
atypical antipsychotic use,30 no consistent trends in prolactin
levels were noted in this study. A low percentage of participants
had TEAEs associated with elevated prolactin levels; however, ab-
normal prolactin levels (≥3 times the ULN) occurred in a higher
percentage of females than males.
Importantly, there were no clinically meaningful changes in
EPS scales or measures of suicidality over the course of the study.
As previously reported,12 8 weeks of treatment with either
RBP-7000 90 mg or RBP-7000 120 mg significantly improved
PANSS total scores, PANSS Positive Scale andGeneral Pathology
Scale, and CGI-S scores versus placebo, whereas PANSS Nega-
tive Scale scores were significantly improved with the 120 mg
dose in acutely ill participants. We now show that with 12 months
of treatment, the mean PANSS total and subscale scores continued
to decrease from baseline to EOS in these participants who en-
rolled in the longer-term study. This finding suggests continued
improvement in acute schizophrenia symptoms after several
months of exposure to RBP-7000.
Among de novo participants, who had been outpatients,
mean PANSS total and subscale scores remained stable through-
out the study.
The main limitations of this study are the open-label nature
of the treatment and that participants in the rollover group had al-
ready shown the ability to tolerate chronic treatment with atypical
antipsychotics, therefore creating some degree of recruitment
bias. Another limitation was an overall discontinuation of 53%,
which might affect the generalization of these results.
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In summary, the overall frequency and severity of TEAEs, in-
cluding injection-site reactions, reduced over time, and no new
safety signals were observed with 12 months of RBP-7000 treat-
ment. Except for injection-site reactions of minor severity that
are expected with SC medications, the safety profile was consis-
tent with that of oral risperidone. Clinical outcome measures im-
proved (rollover) or remained stable (de novo) over the course of
the study. RBP-7000, a once-monthly SC extended-release form
of risperidone, provides additional treatment options for patients
with schizophrenia.
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